EUVIMEDEUVIMED entdecken
Crossref

Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials

Louis, Edouard, Schreiber, Stefan, Panaccione, Remo, Bossuyt, Peter, Biedermann, Luc, Colombel, Jean-Frederic und 47 weitere

Zurich Open Repository and Archive (University of Zurich) · 10.02.2025

DOI: 10.5167/uzh-270721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zurich Open Repository and Archive (University of Zurich), erschienen am 10.02.2025. Verfasst von Louis und 58 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IMPORTANCE The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown. OBJECTIVE To evaluate the efficacy and safety of risankizumab when administered as an induction and a maintenance therapy for patients with ulcerative colitis. DESIGN, SETTING, AND PARTICIPANTS Two phase 3 randomized clinical trials were conducted. The induction trial was conducted at 261 clinical centers (in 41 countries) and enrolled 977 patients from November 5, 2020, to August 4, 2022 (final follow-up on May 16, 2023). The maintenance trial was conducted at 238 clinical centers (in 37 countries) and enrolled 754 patients from August 28, 2018, to March 30, 2022 (final follow-up on April 11, 2023). Eligible patients had moderately to severely active ulcerative colitis; a history of intolerance or inadequate response to 1 or more conventional therapies, advanced therapies, or both types of therapies; and no prior exposure to risankizumab. INTERVENTIONS For the induction trial, patients were randomized 2:1 to receive 1200 mg of risankizumab or placebo administered intravenously at weeks 0, 4, and 8. For the maintenance trial, patients with a clinical response (determined using the adapted Mayo score) after intravenous treatment with risankizumab were randomized 1:1:1 to receive subcutaneous treatment with 180 mg or 360 mg of risankizumab or placebo (no longer receiving risankizumab) every 8 weeks for 52 weeks. MAIN OUTCOMES AND MEASURES The primary outcome was clinical remission (stool frequency score ≤1 and not greater than baseline, rectal bleeding score of 0, and endoscopic subscore ≤1 without friability) at week 12 for the induction trial and at week 52 for the maintenance trial. RESULTS Among the 975 patients analyzed in the induction trial (aged 42.1 [SD, 13.8] years; 586/973 [60.1%] were male; and 677 [69.6%] were White), the clinical remission rates at week 12 were 132/650 (20.3%) for 1200 mg of risankizumab and 20/325 (6.2%) for placebo (adjusted between-group difference, 14.0% [95% CI, 10.0%-18.0%], P < .001). Among the 548 patients analyzed in the maintenance trial (aged 40.9 [SD, 14.0] years; 313 [57.1%] were male; and 407 [74.3%] were White), the clinical remission rates at week 52 were 72/179 (40.2%) for 180 mg of risankizumab, 70/186 (37.6%) for 360 mg of risankizumab, and 46/183 (25.1%) for placebo (adjusted between-group difference for 180 mg of risankizumab vs placebo, 16.3% [97.5% CI, 6.1%-26.6%], P < .001; adjusted between-group difference for 360 mg of risankizumab vs placebo, 14.2% [97.5% CI, 4.0%-24.5%], P = .002). No new safety risks were detected in the treatment groups. CONCLUSION AND RELEVANCE Compared with placebo, risankizumab improved clinical remission rates in an induction trial and in a maintenance trial for patients with moderately to severely active ulcerative colitis. Further study is needed to identify benefits beyond the 52-week follow-up. TRIAL REGISTRATION ClinicalTrials.gov Identifiers: NCT03398148 and NCT03398135.

Schlagwörter

risankizumabulcerative colitismonoclonal antibody therapyinduction therapymaintenance therapyclinical remissionendoscopic responsesubcutaneous administrationadverse eventsdrug safety

Zitieren

APA

Louis, Edouard, Schreiber, Stefan, Panaccione, Remo, Bossuyt, Peter, Biedermann, Luc, Colombel, Jean-Frederic, Parkes, Gareth, Peyrin-Biroulet, Laurent, D'Haens, Geert, Hisamatsu, …, & Group, I. A. C. S. (2025). Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. Zurich Open Repository and Archive (University of Zurich). https://doi.org/10.5167/uzh-270721

Vancouver

Louis, Edouard, Schreiber, Stefan, Panaccione, Remo, et al. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. Zurich Open Repository and Archive (University of Zurich). 2025. doi:10.5167/uzh-270721

BibTeX
@article{Louis2025,
  author = {Louis and Edouard and Schreiber and Stefan and Panaccione and Remo and Bossuyt and Peter and Biedermann and Luc and Colombel and Jean-Frederic and Parkes and Gareth and Peyrin-Biroulet and Laurent and D'Haens and Geert and Hisamatsu and Tadakazu and Siegmund and Britta and Wu and Kaichun and Boland and S, Brigid and Melmed and Y, Gil and Armuzzi and Alessandro and Levine and Phillip and Kalabic and Jasmina and Chen and Su and Cheng and Ling and Shu and Lei and Duan and Rachel, W and Pivorunas and Valerie and Gonzalez, Sanchez and Yuri and D'Cunha and Ronilda and Neimark and Ezequiel and Wallace and Kori and Atreya and Raja and Ferrante and Marc and Loftus and V, Edward and Group, INSPIRE and COMMAND Study},
  title = {Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials},
  journal = {Zurich Open Repository and Archive (University of Zurich)},
  year = {2025},
  doi = {10.5167/uzh-270721}
}
Kostenlos starten →